-Author name in bold denotes the presenting author
-Asterisk * with author name denotes a Non-ASH member
Clinically Relevant Abstract denotes an abstract that is clinically relevant.

PhD Trainee denotes that this is a recommended PHD Trainee Session.

Ticketed Session denotes that this is a ticketed session.

621.O1.6 621. Lymphomas: Translational—Molecular and Genetic: ctDNA and Prognostication

Symposia: Lymphomas: Translational—Molecular and Genetic Program: Oral and Poster Abstracts
Type: Oral
Hematology Disease Topics & Pathways:
Research, clinical trials, Biological therapies, Antibody Therapy, Hodgkin lymphoma, adult, Lymphomas, Translational Research, non-Hodgkin lymphoma, elderly, genomics, bioinformatics, Chimeric Antigen Receptor (CAR)-T Cell Therapies, B Cell lymphoma, Combination therapy, Clinical Research, Diseases, indolent lymphoma, Therapies, Immunotherapy, aggressive lymphoma, Lymphoid Malignancies, Biological Processes, Technology and Procedures, molecular biology, Study Population, Human, Minimal Residual Disease , machine learning, molecular testing, omics technologies
Sunday, December 11, 2022: 12:00 PM-1:30 PM
Great Hall BC (Ernest N. Morial Convention Center)
Moderators:
David W. Scott, PhD, MD, FRACP, FRCPA, British Columbia Cancer Agency and Lisa Giulino Roth, MD, Weill Cornell Medical College
Disclosures:
Scott: Abbvie: Consultancy; AstraZeneca: Consultancy, Honoraria; Incyte: Consultancy; Janssen: Consultancy, Research Funding; Roche: Research Funding; NanoString: Patents & Royalties.
12:00 PM

Stefan K. Alig, MD1, Mohammad Shahrokh Esfahani, PhD1*, Michael Y. Li, BS2*, Ragini Malika Adams, MD3*, Andrea Garofalo4*, Michael C. Jin5*, Mari Olsen1*, Adèle Telenius2*, Brian Sworder, MD, PhD6, Joseph Schroers-Martin, MD5, Daniel A. King, MD, PhD1*, Cédric Rossi, MD, PhD1*, Andre Schultz, PhD1*, Karan R. Kathuria1*, Chih Long Liu, PhD5*, Valeria Spina7*, Lieselot Buedts8*, Jamie E. Flerlage, MD, MS9, Sharon M. Castellino, MD, MSc10, Ranjana H. Advani, MD11, Davide Rossi, MD, PhD7, Ryan C. Lynch, MD12, Olivier Casasnovas, MD13*, David M. Kurtz, MD, PhD5, Lianna J. Marks, MD3, Michael P. Link, MD14, Marc André, MD15*, Peter Vandenberghe, MD, PhD16, Christian Steidl2*, Maximilian Diehn, MD, PhD17* and Ash A. Alizadeh, MD, PhD18

1Department of Medicine, Divisions of Oncology and Hematology, Stanford University, Stanford, CA
2Centre for Lymphoid Cancer, BC Cancer, Vancouver, BC, Canada
3Department of Pediatrics, Stanford University, Stanford, CA
4Divisions of Oncology and Hematology, Department of Medicine, Stanford University, Stanford, CA
5Divisions of Oncology and Hematology, Department of Medicine, Stanford University School of Medicine, Stanford, CA
6Division of Oncology, Department of Medicine, Stanford University School of Medicine, Stanford, CA
7Institute of Oncology Research, Bellinzona, Switzerland
8Department of Human Genetics, KU Leuven, Leuven, Belgium
9Department of Oncology, St. Jude Children's Research Hospital, Memphis, TN
10Department of Pediatrics, Emory University School of Medicine, Atlanta, GA
11Department of Medicine, Division of Oncology, Stanford University, Stanford, CA
12Seattle Cancer Care Alliance, Fred Hutchinson Cancer Research Center, Seattle, WA
13Hematology Department, University Hospital F. Mitterrand and Inserm UMR 1231, Dijon, France
14Department of Pediatrics, Stanford University, Palo Alto, CA
15Department of Haematology, Université Catholique de Louvain, CHU UCL Namur, Yvoir, Belgium
16Department of Hematology & Department of Human Genetics, UZ & KU Leuven, Leuven, Belgium
17Department of Radiation Oncology, Stanford University School of Medicine, Stanford, CA
18Divisions of Oncology and Hematology, Department of Medicine, Stanford University School of Medicine, San Mateo, CA

12:15 PM

Alex F. Herrera, MD1, Ronald McCord, PhD2*, Patrick Kimes, PhD2*, Fabrice Jardin, MD, PhD3*, Georg Lenz, MD, Prof.4, Marek Trneny, MD5, Christopher R. Flowers, MD6, Laurie H. Sehn, MD, MPH7, Gilles Salles, MD, PhD8, Jeff P. Sharman, MD9, Hervé Tilly, MD, PhD3, Jonathan W. Friedberg, MD, MMSc10, Charles Herbaux11, Matthew J. Matasar, MD, MS8, Corinne Haioun, MD, PhD12, Samuel Tracy, PhD2*, Jamie Hirata, PharmD2, Calvin Lee, MD2, Yanwen Jiang, PhD2* and Franck Morschhauser, MD, PhD13*

1City of Hope, Duarte, CA
2Genentech, Inc., South San Francisco, CA
3Centre Henri-Becquerel and University of Rouen, Rouen, France
4University Hospital Münster, Münster, Germany
5Charles University, General Hospital, Prague, Czech Republic
6M.D. Anderson Cancer Center, Houston, TX
7BC Cancer Centre for Lymphoid Cancer and University of British Columbia, Vancouver, BC, Canada
8Memorial Sloan Kettering Cancer Center, New York, NY
9Willamette Valley Cancer Institute and Research Center, Florence, OR
10University of Rochester, Rochester, NY
11University of Montpellier, Montpellier, France
12Groupe Hospitalier Henri Mondor-Chenevier, Créteil, France
13University of Lille, Centre Hospitalier Universitaire de Lille, Lille, France

12:30 PM

Brian Sworder, MD, PhD1, David M. Kurtz, MD, PhD1, Stefan K. Alig, MD2, Matthew J Frank, MD, PhD3, Navika D. Shukla, MD4*, Andrea Garofalo5*, Charles Macaulay, MSc, BA5*, Mohammad Shahrokh Esfahani, PhD2*, Mari Olsen2*, James Hamilton III6*, Hitomi Hosoya, MD, PhD6, Mark P Hamilton, MD7, Jay Y. Spiegel, MD, FRCPC8, John H. Baird, MD8, Mia Carleton2*, Alexander F. M. Craig, MD, MPhil9, Sheren F. Younes, MD, PhD10*, Bita Sahaf, PhD8*, Natasha Sheybani, PhD1*, Joseph Schroers-Martin, MD6, Chih Long Liu, PhD6*, Jean S Oak, MD, PhD10*, Michael C. Jin6*, Sara Beygi Beygi, MD11, Andreas Hüttmann, MD12, Christine Hanoun13*, Ulrich Dührsen, Prof, MD, PhD13*, Jason Westin, MD14, Michael S. Khodadoust, MD PhD15, Yasodha Natkunam, MD, PhD16, Robbie G. Majzner, MD17, Crystal L. Mackall, MD18,19, Maximilian Diehn, MD, PhD20*, David B. Miklos, MD, PhD8 and Ash A. Alizadeh, MD, PhD21

1Division of Oncology, Department of Medicine, Stanford University School of Medicine, Stanford, CA
2Department of Medicine, Divisions of Oncology and Hematology, Stanford University, Stanford, CA
3Division of Blood and Marrow Transplantation and Cellular Therapy, Department of Medicine, Stanford University School of Medicine, Palo Alto, CA
4Department of Medicine, Divisions of Hematology & Oncology, Stanford University, Palo Alto, CA
5Divisions of Oncology and Hematology, Stanford University School of Medicine, Stanford, CA
6Divisions of Oncology and Hematology, Department of Medicine, Stanford University School of Medicine, Stanford, CA
7Divisions of Oncology and Hematology, Department of Medicine, Stanford University School of Medicine, Palo Alto, CA
8Division of Blood and Marrow Transplantation and Cellular Therapy, Department of Medicine, Stanford University School of Medicine, Stanford, CA
9Division of Oncology, Department of Medicine, Stanford University, Stanford, CA
10Department of Pathology, Stanford University School of Medicine, Stanford, CA
11Divisions of Hematology and Oncology, Department of Medicine, Stanford University School of Medicine, Stanford, CA
12Department of Hematology, West German Cancer Center, University Hospital Essen, University of Duisburg-Essen, Essen, NRW, Germany
13Department of Hematology, West German Cancer Center, University Hospital Essen, University of Duisburg-Essen, Essen, Germany
14The University of Texas MD Anderson Cancer Center, Houston, TX
15Department of Medicine, Division of Oncology & Department of Dermatology, Stanford University School of Medicine, Stanford, CA
16Stanford University School of Medicine, Stanford, CA
17Department of Pediatrics, Stanford University School of Medicine, Palo Alto, CA
18Center for Cancer Cell Therapy, Stanford University School of Medicine, Stanford, CA
19Divisions of Hematology and Oncology, Department of Pediatrics, Stanford University School of Medicine, Stanford, CA
20Department of Radiation Oncology, Stanford University School of Medicine, Stanford, CA
21Divisions of Oncology and Hematology, Department of Medicine, Stanford University School of Medicine, San Mateo, CA

12:45 PM

Eva Hoster1,2*, Marie-Helene Delfau3,4*, Elizabeth A. Macintyre, PhD, FRCP, FRCPath5,6, Linmiao Jiang, MSc1*, Stephan Stilgenbauer, MD7, Ursula Vehling-Kaiser8*, Gilles Salles, MD, PhD9,10, Catherine Thieblemont, MD, PhD11, Hervé Tilly, MD, PhD12, Lothar Kanz13, Pierre Feugier, MD14*, Kai Huebel, MD15*, Christian Schmidt, MD2*, Vincent Ribrag, MD16, Hanneke Kluin-Nelemans, MD17*, Martin Dreyling, MD2 and Christiane Pott18*

1Institute for Medical Information Processing, Biometry and Epidemiology, LMU Munich, Munich, Germany
2Department of Internal Medicine III, LMU University Hospital, Munich, Germany
3Immunology Biology, Mondor University Hospital, Créteil, France
4INSERMU955 équipe 9, Institut Mondor de Recherche Biomédicale, Créteil, France
5Institut Necker Enfants Malades, Université de Paris (Descartes), Paris, France
6Laboratory of Onco-Hematology, Necker University Hospital, Paris, France
7Department of Internal Medicine III, University Hospital Ulm, Ulm, Germany
8UBAG MVZ Dr. Vehling-Kaiser GmbH, Landshut, Germany
9Hospices Civils de Lyon, Université Claude Bernard, Centre Hospitalier Lyon-Sud, Pierre Bénite, France
10Department of Medicine, Lymphoma Service, Memorial Sloan Kettering Cancer Center, New York, NY
11Hemato-Oncology, Hôpital Saint-Louis, APHP, University of Paris, Paris, France
12Department of Hematology and U1245, Centre Henri Becquerel and University of Rouen, Rouen, France
13Department of Oncology, Hematology, Immunology, Rheumatology and Pulmonology, University Hospital Tuebingen, Tuebingen, Germany
14Department of Hematology, Henri Poincaré University, CHU NANCY BRABOIS, Vandoeuvre Les Nancy, France
15Klinik I für Innere Medizin, University of Cologne, Cologne, Germany
16DITEP-Hematology, Inserm U1170, Institut Gustave Roussy, Villejuif, France
17Department of Hematology, University Medical Center Groningen, University of Groningen, Groningen, Netherlands
18Clinic for Internal Medicine II - Haematology, Oncology, University Clinic Schleswig-Holstein, Kiel, Germany

1:00 PM

Herve Ghesquieres, MD, PhD1*, Youenn Drouet, PhD2*, Susan L. Slager, PhD3, Franck Morschhauser, MD, PhD4*, Sara Galimberti, MD5*, Dennis P. Robinson3*, Emilie Thomas6*, Anne J. Novak, PhD7, Luc Xerri, MD, PhD8*, Stefano Luminari, MD9, Aurelie Verney10*, Camille Laurent, MD, PhD11*, Lisa M. Rimsza, MD12, Thomas M. Habermann, MD13, Massimo Federico, MD14, Brian K. Link, MD15, Gilles Salles, MD, PhD16 and James R. Cerhan, MD, PhD3

1Department of Hematology, Lyon Sud University Hospital/Hospices Civils de Lyon, Pierre Benite, France
2Prevention and genetic epidemiology Unit, Centre Leon Berard, Lyon, France
3Department of Health Sciences Research, Mayo Clinic, Rochester, MN
4Service des Maladies du Sang, CHU Lille, Lille, France
5UO Ematologia, Azienda Ospedaliero Universitaria Pisana, Pisana, Italy
6Centre Leon Berard, Centre de recherche en cancérologie de Lyon, INSERM 1052, CNRS 5286, Lyon, France
7Division of Hematology, Mayo Clinic, Rochester, MN
8Bio-Pathology Department, Institute Paoli-Calmettes, Marseille, France
9Hematology Unit, Azienda USL-IRCCS di Reggio Emilia, REGGIO EMILIA, Italy
10Centre International de Recherche en Infectiologie, Lymphoma Immuno Biology Team, INSERM 1111, Université Claude Bernard Lyon 1, Lyon, France
11Department of Pathology, Institut Universitaire du Cancer Toulouse Oncopole, Toulouse, France; Cancer Research Center of Toulouse, INSERM UMR 1037, ERL5294 CNRS, Université Toulouse III-Paul-Sabatier, Toulouse, France
12Division of Hematopathology, Mayo Clinic - Scottsdale, Scottsdale, AZ
13Division of Hematology, Department of Medicine, Mayo Clinic, Rochester, MN
14Surgical, Medical and Dental Department of Morphological Sciences related to Transplant, Oncology and Regenerative Medicine, University of Modena and Reggio Emilia, Modena, Italy
15Division of Hematology, Oncology, and Blood & Marrow Transplantation, University of Iowa, Iowa City, IA
16Department of Medicine, Lymphoma Service, Memorial Sloan Kettering Cancer Center, New York, NY

1:15 PM

Laura K Hilton, PhD1,2*, Henry S. Ngu2*, Brett Collinge2,3*, Kostiantyn Dreval, PhD1,4*, Susana Ben-Neriah, MSc2*, Christopher K Rushton1*, Jasper Wong2*, Manuela Cruz, BSc1*, Andrew Roth5*, Merrill Boyle, BSc2*, Barbara Meissner2*, Graham W. Slack, MD2,3, Pedro Farinha, MD, PhD2,3*, Jeffrey W. Craig, MD, PhD2,3*, Alina S. Gerrie, MD, MPH, FRCPC2,6, Ciara L. Freeman, MSc, FRCPath, MBBChir, MRCP7, Diego Villa, MD2,6, Kerry J. Savage, MD, MSc, FRCPC2,6, Laurie H. Sehn, MD, MPH2,6, Marco A. Marra2,4,8, Aly Karsan, MD4, Christian Steidl2,3*, Ryan D. Morin2,4,9 and David W. Scott, PhD, MD, FRACP, FRCPA2,10

1Department of Molecular Biology & Biochemistry, Simon Fraser University, Burnaby, BC, Canada
2Centre for Lymphoid Cancer, BC Cancer, Vancouver, BC, Canada
3Department of Pathology and Laboratory Medicine, University of British Columbia, Vancouver, BC, Canada
4Canada's Michael Smith Genome Sciences Centre, BC Cancer, Vancouver, BC, Canada
5BC Cancer, Department of Molecular Oncology, Vancouver, BC, Canada
6Division of Medical Oncology, University of British Columbia, Vancouver, BC, Canada
7Department of Blood and Marrow Transplant and Cellular Immunotherapy, H. Lee Moffitt Cancer Center & Research Institute, Tampa, FL
8Department of Medical Genetics, University of British Columbia, Vancouver, BC, Canada
9Department of Molecular Biology and Biochemistry, Simon Fraser University, Burnaby, BC, Canada
10Department of Medicine, University of British Columbia, Vancouver, BC, Canada

*signifies non-member of ASH